Antibiotics Ineffective In Treating Chronic Back Pain: Study

Amid continuing concerns within the medical community about the overuse of antibiotics, which may result in the spread of antibiotic-resistent “superbug” infections, the findings of a new study suggest that the drugs provide little or no relief for treatment of chronic low back pain.

In findings published last month in the medical journal BMJ, researchers from Norway indicate there is no support for the practice of offering antibiotics to patients as a treatment for low back pain. Instead, they called for other interventions to be explored.

Researchers conducted a small double-blind study involving 180 patients treated at six hospitals in Norway, from June 2015 to September 2017. The patients experienced chronic low back pain or previous disc herniation. Additionally, they experienced one of two “Modic” changes, which is a change in the discs seen on imaging and can include signs of inflammation.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Researchers hypothesized some patients suffering from back pain with Modic changes might be suffering from a low-grade infection which would be the cause of the inflammation. Degenerative discs may provide a perfect place for the infection to grow, thus, treating low back pain in those cases could help relieve the underlying infection and eventually the pain.

Patients were randomly assigned to either three months of oral treatment of antibiotics or a placebo three times per day. The antibiotic group received 750 mg of amoxicillin daily.

Three months of treatment with amoxicillin failed to provide a clinically significant difference in the level of back pain experienced by patients compared with placebo. In addition, 56% of patients in the amoxicillin group experienced at least one drug related adverse event, compared to 34% of patients in the placebo group.

The amoxicillin group had lower disability scores than the placebo group, but it was a difference of only 1.6 points, which did not meet the threshold of being clinically important.

Chronic low back pain occurs in one-quarter of the adult population in the United States and leads to millions of annual office visits a year, missed workdays, and medical costs.

Unnecessary antibiotic use contributes to the proliferation of antibiotic resistant bacteria, experts warn. So-called “superbug” evolution is outpacing new antibiotic development as more and more bacteria becomes resistant to antibiotic treatment, according to recent research.

Recently, rare antibiotic resistant infections were found in 27 states across the U.S. Despite the known risks of superbug proliferation, health experts warn that antibiotics are still prescribed inappropriately in instances where they are not needed and do not treat the infection or problem in questions.

The findings of the new study do not support the use of antibiotic treatment for chronic low back pain and underscore the need for studies like this to highlight situations where antibiotics are unnecessary, the researchers concluded.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Angiodynamics LifePort Lawsuit Filed Over Risk of the Port Catheters Failing, Causing Severe Injury
Angiodynamics LifePort Lawsuit Filed Over Risk of the Port Catheters Failing, Causing Severe Injury (Posted today)

Complaint comes as a panel of federal judges are scheduled to hear oral arguments later this month, to determine whether all AngioDynamics port catheter lawsuits filed in U.S. District Courts nationwide should be centralized before one judge.

Depo-Provera Meningioma Brain Tumors Risks May Have Been Ignored by Pfizer for Decades
Depo-Provera Meningioma Brain Tumors Risks May Have Been Ignored by Pfizer for Decades (Posted 4 days ago)

After decades of medical research and reported Depo-Provera side effects, Pfizer should have known that its birth control shot increases the risks of meningioma brain tumors, yet failed to warn women or the medical community.